MNC-168 / Moon (Guangzhou) Biotech - LARVOL DELTA

Live biotherapeutic enterococcus lactis MNC-168 promotes the efficacy of immune checkpoint blockade in cancer therapy by activating STING pathway via bacterial membrane vesicles. (PubMed, Gut Microbes) - "Furthermore, we have confirmed the safety profile of MNC-168 and its enhancing effect on Anti-PD-1 activity across multiple preclinical models, as well as its potential clinical relevance to Anti-PD-1 therapy. These findings suggest that MNC-168 could represent a promising strategy for cancer therapy and has the potential to improve the efficacy of current immunotherapies."

Checkpoint inhibition • Journal • Oncology • STING

Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Moon (Guangzhou) Biotechnology Co., Ltd. | Not yet recruiting ➔ Completed | N=24 ➔ 12

Enrollment change • IO biomarker • Trial completion • Solid Tumor

Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Moon (Guangzhou) Biotechnology Co., Ltd.

IO biomarker • New P1 trial • Oncology • Solid Tumor

[VIRTUAL] Preclinical monotherapeutic and anti-PD-1 synergistic anti-tumor efficacy of MNC-168, a novel human-derived live biotherapeutic product. (ASCO 2021) - "MNC-168 is highly potently used as a first-in-class live biotherapeutic product for cancer monotherapy and promoting efficacy of ICI-mediated cancer immunotherapy."

IO biomarker • Preclinical • Colorectal Cancer • Fibrosarcoma • Gastrointestinal Cancer • Hepatocellular Cancer • Immune Modulation • Inflammation • Kidney Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CD4 • CD8